Aardvark Therapeutics ( NASDAQ:AARD – Get Free Report ) ‘s stock had its “sector perform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a research note issued to investors on Thursday, Benzinga reports. They currently have a $6.00 price objective on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 11.98% from the stock’s current price.
A number of other research analysts have also commented on AARD. Wall Street Zen upgraded shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright restated a “neutral” rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research report on Monday, July 20th. Finally, Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Aardvark Therapeutics has a consensus rating of...